These results provide the proof of concept that chimeric rat/human HER2 plasmids can be used as effective vaccines for any HER2-CP with the advantage of being not limited to specific MHC.
INTRODUCTION
The ErbB-2 (neu in rat and HER2 in humans) tyrosine kinase receptor is an oncoantigen overexpressed by a variety of tumors (1) . The driving role of HER2 in epithelial oncogenesis as well as its selective overexpression on malignant tissues makes it an ideal target for immunotherapy (2) . Passive immunotherapy with monoclonal antibodies (mAb) such as trastuzumab, and receptor tyrosine kinase inhibitors, i.e. lapatinib, are HER2-targeted therapies currently used for the treatment of HER2-overexpressing breast cancers (3, 4) . Unfortunately, the therapeutic efficacy of both these therapies is abolished by primary and acquired tumor resistance, probably due to the emergence of compensatory activities via alternative signaling pathways (5, 6) . Active immunotherapy against HER2 might thus represent an alternative strategy. HER2/neu is a self-antigen and thus tolerogenic. Based on HER2-transgenic mouse models, it is now evident that this tolerogenicity causes deletion or inactivation of reactive high-avidity T cells against neu, thereby leading to self-tolerance (7). Nevertheless, low avidity self-specific T cells can be isolated from tolerant hosts and there are reports that such cells when activated and expanded by a vaccine, can give an antitumor response (8) .
Similarly, expansion of specific T cells has been elicited in patients following vaccination with subdominant (9) or heteroclitic peptides (10, 11) ; however, clinical responses have not yet been obtained (12) , suggesting that additional mechanisms besides central tolerance contribute to T cell dysfunction in cancer patients.
A large body of data have been accumulated in the last decade about the role of T regulatory (Treg) cells in inducing T cell peripheral tolerance and about the "exhaustion" of T cells with expression of inhibitory check-point receptors typical of patients with chronic infections or cancer (13) . Author Manuscript Published OnlineFirst on March 25, 2014 ; DOI: 10.1158/1078-0432.CCR- Several studies have reported increased frequencies of Treg in blood, draining lymph nodes, and tumor tissues, associating an impaired immune response to cancer with a high frequency and/or hyperactivity of Treg (14) . The majority of these Treg arise from tumor-induced conversion of conventional CD4 + T cells and differ from thymus-derived natural Treg that play a crucial role in regulating the immune response and in maintaining immune homeostasis in healthy individuals (for a review see 15) .
To overcome tumor-driven T cell dysfunction in cancer patients, the use of heterologous peptides may be advantageous. In case of patients with HER2-overexpressing cancers (HER2-CP) the use of heterologous peptides characterized by the presence of critical amino acid substitutions that markedly improve their immunogenicity may induce activation of non-tolerized, non-exhausted, and self-cross reactive low-affinity T cell clones (16) . These, in turn, release cytokines that enhance immune recognition in a paracrine way and eventually activate auto-reactive B cells.
Chimeric vaccines containing both self human HER2 and heterologous rat neu DNA sequences induced a more potent cellular and humoral antitumor immunity than self sequence alone (17, 18) . However, no data on their potential efficacy in humans are currently available. Compared to peptide-based vaccines, DNA vaccination has been shown to be more advantageous (19) . Indeed, DNA vaccines offer a precise strategy for delivering antigens to the immune system as they can be expressed on cell surfaces or, more commonly, as peptides in association with the MHC class I or II molecules, and their application is not limited to one or few specific MHC molecules (for a review see 20, 21) . A first pilot clinical trial from Norell and colleagues demonstrated promising feasibility, safety and tolerability of vaccination with DNA coding for the full-length HER2 molecule in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-2 in patients with advanced breast cancer already receiving trastuzumab, but with limited clinical effects (22) .
Research. Here we evaluated the feasibility of using DNA coding for chimeric rat/human HER2 as a tool to counteract the dysfunction of T cells from HER2-CP. We transfected monocyte-derived dendritic cells (DCs) from HER2-CP and healthy subjects (HS) with DNA plasmids coding for human, rat or chimeric rat/human HER2. Only DCs transfected with the chimeric plasmids were able to elicit a specific anti-HER2 response by T cells from HER2-CP. Their ability relies on the activation of a significant lower number of Treg cells and lower production of IL-10 and TGFβ1 that results in the rescue from tumorinduced immune dysfunction.
In conclusion, these results provide the proof of concept that vaccination with chimeric rat/human HER2 DNA plasmids could be an effective therapeutic option for all HER2-CP, with the advantage of being not limited to specific MHC.
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Materials and Methods

Human specimens
Human peripheral blood leukocytes (PBL) were isolated by Ficoll-Hypaque (Lonza) gradient centrifugation from heparinized venous blood of HS (n=22) provided by the local Blood Bank (Torino, Italy), and cancer patients (n=44), not previously treated with radio-or chemo-therapy. Patients with pancreatic adenocarcinoma (PDAC, n=16) or breast cancer (BC, n=28) recruited at the Centro Oncologico Ematologico Subalpino (COES), AO Città della Salute e della Scienza di Torino, Torino, Italy, with informed consent were included in the study. Blood samples were immediately processed after drawing. Tumors from PDAC and BC patients were evaluated for HER2 positivity by immunohistochemistry (IHC). Patients bearing HER2
+ tumors that were classified as 3+ or 2+ by IHC were classified as HER2-CP (Supplementary Table S1 ). Patients with tumors with a 0-1 IHC score, i.e HER2 negative, (n=5) were used as a control group (CTRL-CP; Supplementary Table S2 ). To determine human leukocyte antigen (HLA)-A2 positivity, PBL were incubated with anti-HLA-A2-PE mAb (clone BB7.2, BD Pharmingen) and expression was evaluated by flow cytometry.
Cell cultures
Monocyte-derived DC generation was conducted as previously described (23) .
TNF-α (50 ng/ml) and IL-1β (50 ng/ml, Peprotech) were added for the final 24 hours to induce DC maturation. CD14-depleted PBL were stored in liquid nitrogen until use.
Thawed lymphocytes (>80% viability and >50% recovery) were cultured for 7 days with autologous transfected-DCs at 20:1 ratio in RPMI 1640 medium with 10% heat-inactivated human serum AB (Lonza) at 2 x 10 6 /ml. At day 3, one third of supernatants was collected and replaced with fresh complete medium plus IL-7 (10 ng/ml, PeproTech).
The human pancreatic cancer cell line CF-PAC1 and the human ovarian carcinoma cell 
Plasmids and nucleofection
Plasmid pVAX1 was the backbone for all the DNA constructs used for transfection of DCs.
All four plasmids code for the extracellular and transmembrane domains of HER2, as previously described (17) . HuHuT codes for the fully human, and Rat for the fully rat HER2 molecule. RHuT codes for the first two extracellular domains of rat HER2 and the remaining part of human HER2. Conversely, HuRT codes for the first two extracellular domains of human HER2 and the remaining part of rat HER2. Large-scale preparation of the plasmids was carried out using EndoFree Plasmid Maxi kits (Qiagen). Mature DCs were harvested on day 6 of culture, resuspended in 100μl of electroporation buffer (DC transfection kit, Amaxa, Lonza) and mixed with 5μg of plasmid DNA. Electroporation was performed using the Nucleofector program U-002 (Amaxa, Lonza). After electroporation, cells were immediately transferred to 2 ml of complete media and cultured at 37°C.
Efficiency of transfection was analyzed by flow cytometry after 6 hours following transfection. Transfected DCs were fixed, permeabilized, and stained with mouse α-rat-or α-human-HER2 mAb (Calbiochem) followed by αmouse-PE (BD Biosciences). FACS analysis of cell surface molecules on transfected DCs was carried out using the following mAb αCD80-PE (clone 2D10), αCD86-PE (clone IT2.2), αCD40-PE (BD Biosciences), αCD83-PE (clone HB15e) and αHLA-DR-PerCP (Biolegend).
ELISpot assay
To detect Treg cells, PBL were stained with αCD4-PerCP (clone OKT4), αCD25-PE (clone BC96) (Biolegend) mAbs on the cell surface, treated with Fixation and Permeabilization buffer (eBioscience) and stained with αFoxp3-FITC (clone 236A/E7) mAb (eBioscience).
To detect proliferating cells, PBL were stained with αCD4-PerCP and αCD8-PE (clone HIT8a) (Biolegend) mAbs on the cell surface, treated with Fixation and Permeabilization buffer and stained with αKi-67-APC (clone Ki67) mAb (Biolegend).
For intracellular staining, 10 6 lymphocytes, recovered after 7 days-co-culture with transfected DCs, were resuspended in AIM-V, and restimulated with 1 μg/ml coated αCD3
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Immunohistochemistry
Tumors were harvested at necropsy, fixed in 10% formalin and dehydrated in 70% ethanol. The fixed samples were then embedded in paraffin and four sequential serial sections/tumor were obtained. Sections were processed for IHC using αCD8 (clone C8/144B, Roche), αCD4 (clone 4B12) or αKi-67 (clone Mib-1) mAb that were applied using the Ultra BenchMark automated stainer (Ventana, Roche). Images were acquired using positive nuclei were quantified by measuring the percentages of Ki-67+, CD8+, CD4+ cells, respectively, among the total mononuclear cells.
Ethics statement
The human studies were conducted according to the Declaration of Helsinki principles. Human investigations were performed after approval of the study by the Scientific Ethics Committee of AO Città della Salute e della Scienza di Torino, Torino, Italy 
Statistical analysis
Statistical analyses were performed using Prism 5.0 GraphPad Software and results are expressed as the mean ± SEM. One-way ANOVA was performed, followed by Table S1 ), as previously reported (23) . CD14 + cells derived from HER2-CP express higher amounts of IL-4Rα and lower levels of HLA-DR molecules compared to those from HS ( Supplementary Fig. S1A ). These data are in line with current notions indicating an expansion of a monocyte population with a myeloid-derived suppressor cell-like phenotype that correlates with tumor growth (24) .
Despite these differences in their precursors, mDCs from both HER2-CP and HS expressed similarly high levels of the maturation markers and co-stimulatory molecules CD83, CD80, CD86, CD40 and HLA-DR ( Supplementary Fig. S1 , B and C).
Nucleofection of the four plasmids (self HuHuT, chimeric HuRT and RHuT, heterologous Rat) always gave a range of 35-45% positive mDCs from both HS and HER2-CP ( Supplementary Fig. S2A ), thus showing high reproducibility ( Supplementary Fig. S2B ).
DCs transfected with pVAX1 plasmid (empty-DCs) were used as control. These results indicate that mDCs generated from HER2-CP display similar features and potential stimulatory capacity as those from HS.
To assess the ability of self versus heterologous and chimeric DNA plasmids to induce a specific anti-HER2 CD8 T cell response, mDCs generated from HS and HER2-CP were transfected with the different plasmids specified above, and used to stimulate autologous T cells. After 7 days of co-culture, CD8 T cells from HS stimulated with self
HuHuT-or chimeric HuRT-and RHuT-DCs displayed higher proliferative ability compared to those stimulated with empty-DCs, while heterologous Rat-DCs had no effect
Research. Fig. S3, A and B) . By contrast, only chimeric RHuT-DCs induced proliferation of CD8 T cells from HER2-CP ( Supplementary Fig. S4, A and B Fig. S3C ). By contrast, only chimeric RHuT-DCs from HER2-CP led to the expression of both IFN-γ and perforin by CD8 T cells; transfection with the other plasmids had low or no effect (Supplementary Fig.   S4C ). The concomitant expression of IFN-γ and perforin in CD8 T cells implies their potential cytotoxic ability.
The specificity of the CD8 T cell response against human HER2 was assessed by construct RHuT codes for both E75 and GP2 peptides, while HuRT only for E75.
Compared to control empty-DCs, self HuHuT-and chimeric RHuT-DCs from HS were able to activate a significant number of IFN-γ-releasing T cells in response to both peptides, while chimeric HuRT-DCs only in response to the GP2 peptide (Fig. 1A) . By contrast, in CP only chimeric RHuT-DCs were able to elicit peptide-specific IFN-γ production ( Fig. 2A) .
Moreover, T cells activated by HuHuT-, HuRT-, RHuT-DCs and Rat-DCs from HS were able to kill HER2 + CF-PAC1 and SKOV-3-A2 tumor cells, as evaluated by a 4-hour 51
Cr release assay (Fig. 1B) . In T cells from HER2-CP,, stimulation with the chimeric
RHuT-DCs seems to be more efficient in inducing cytotoxic activity (Fig. 2B) 
Overall, these data suggest that DCs transfected with the chimeric plasmid RHuT were able to overcome tumor-induced dysfunction of T cells from HER2-CP and to induce a specific anti-HER2 CD8 cytotoxic response.
Chimeric HER2-transfected DCs from HER2-CP elicit a Th1 response
In order to activate a stronger and longer-lasting antitumor response, vaccines must not only elicit cytotoxic CD8 T cells but also Th1 cells (27) . We first evaluated CD4 T cells in in vitro proliferation. All self HuHuT-, chimeric HuRT-and RHuT-and heterologous RatDCs from HS triggered proliferation of autologous CD4 T cells to similar levels, as evaluated by Ki-67 staining (Fig. 3, A and B) . Conversely, only chimeric HuRT-and RHuTDCs from HER2-CP stimulated a significantly higher proliferation of CD4 + T cells compared to empty-, heterologous Rat-and self HuHuT-DCs (Fig. 3 , A and C). After 7 days of co-culture, activated T cells were restimulated with anti-CD3/CD28 mAb and analyzed for IFN-γ expression. Chimeric HuRT-and RHuT-DCs from HER2-CP triggered a higher percentage of IFN-γ-producing CD4 T cells compared to the other groups (Fig. 3E ).
By contrast, DCs from HS transfected with the different plasmids all resulted in a similar increase in IFN-γ-producing CD4 T cells compared to empty-DCs (Fig. 3D ).
This evidence suggests that DCs from HER2-CP transfected with both the chimeric HER2 plasmids are able to trigger a Th1 response.
T cells from HER2-CP activated by chimeric HuRT-and RHuT-DCs impede HER2
+ tumor growth in vivo. of IFN-γ were indeed detected in supernatants derived from co-cultures with chimeric HuRT-and RHuT-DCs compared to the other co-cultures with self or heterologous HER2 (Fig. 5A) , consistent with the higher intra-cytoplasmic expression of IFN-γ in both CD4 and CD8 T cells ( Supplementary Fig. S4C and 3E ).
Next we evaluated whether T cells from HER2-CP activated in vitro,
To verify the role of IFN-γ in the inhibition of in vivo tumor growth, SKOV-3-A2 tumor cells were cultured for 48 hours with supernatants derived from the different co-cultures.
Supernatants from both chimeric RHuT-and HuRT-DCs co-cultures induced higher percentages of apoptotic cells in comparison to those from empty-DC co-cultures (Fig. 5, B and C). The addition of IFN-γ neutralizing mAb to the supernatants abrogated this effect.
Moreover, when SKOV-3-A2 cells were cultured for 48 hours with increasing concentrations of recombinant human IFN-γ, from 0.5 to 8 ng/ml, a dose response apoptotic induction was observed (Fig. 5 D) .
These results suggest that the antitumor response elicited by chimeric RHuT-and HuRTDCs may be in part mediated by IFN-γ. However, the more potent antitumor response induced by co-culture with RHuT-DCs seems to also involve perforin-expressing CD8 T cells.
The inability of self HuHuT-DCs to activate T cells from HER2-CP against HER2 is dependent on IL-10 and TGFβ1 production.
Many publications have already reported an expansion of tumor-induced regulatory cells in the peripheral blood of cancer patients (29, 30 ). As we stimulated T cells with transfected DCs, it is conceivable that regulatory cells, already expanded in HER2-CP ( Supplementary Fig. S5A ) could also be activated and expanded (31) . However, we did not observe any differences in the percentage of CD4 To assess whether IL-10 and TGFβ1 production had a role in inhibiting the CD8 and CD4 T cell response against human HER2, lymphocytes from HER2-CP were activated with self HuHuT-DCs in the presence of anti-IL-10 and/or anti-TGFβ1 neutralizing mAb.
Neutralization of both cytokines increased the ability of HuHuT-DCs to induce IFN-γ and perforin expression by CD8 T cells (Fig. 6C) , and also a specific response against the immunodominant E75 and GP2 peptides (Fig. 6D) as well as RHuT-DCs ( Fig. 2A) . In addition, the ability of CD4 T cells to produce IFN-γ was also increased (Fig. 6E) . Overall, these data strongly suggest that the presentation of self HER2 could promote suppressive mechanisms, such as IL-10 and TGFβ1 production that impair antigen-specific CD8 and CD4 T cell activation.
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Based on our results we hypothesized that, in HER2-CP, HER2-specific tumorinduced regulatory cells are expanded and that self HuHuT-DCs could stimulate these cells to produce IL-10 and TGF-β1. In order to verify this hypothesis, we evaluated if transfected DCs stimulated Treg cells to secrete these cytokines. Interestingly, HuHuTDCs elicited higher expression of IL-10 ( Fig. 6F) and TGFβ1-associated LAP (Fig. 6G) Table S2 ) were transfected and cocultured with autologous lymphocytes. In this case self HuHuT-DCs did not suppress the production of IFN-γ and perforin by CD8 T cells, (Supplementary Fig. S6A ) similarly to what was observed in co-cultures from HS ( Supplementary Fig. S3C ). Moreover, self HuHuT-DCs were also able to expand CD4 T cells expressing IFN-γ, as for chimeric HuRT-and RHuT-DCs and heterologous Rat-DCs (Supplementary Fig. S6B ). Notably, self
HuHuT-DCs from CTRL-CP did not induce suppressive mechanisms such as IL-10 ( Supplementary Fig. S6C ) and TGFβ1 production ( Supplementary Fig. S6D ).
These data indicate an increase of HER2-specific regulatory cells in HER2-CP as a result of antigen overexpression that can be restimulated by the total self-sequence of
HER2.
DISCUSSION
In the current study, we demonstrated, for the first time, that DNA plasmids coding for chimeric rat/human HER2 are able to elicit an effective immune response by T cells from HER2-CP and efficiently circumvent T cell dysfunction. No T cell response against HER2 was induced by autologous DCs transfected with DNA plasmids coding for self or fully heterologous HER2. By contrast, both self HuHuT-and chimeric RHuT-DCs from HS, as well as those from CTRL-CP, in which there are no HER2-specific negative regulatory mechanisms, showed a similar induction of HER2-specific CD8 T cell response.
Anti-HER2 vaccines consisting of MHC class I restricted peptides demonstrated the ability to elicit immunological responses and some clinical benefits in disease-free breast cancer patients (34) . However, the efficacy of the immune response required for antigen-specific tumor inhibition depends not only on correct antigen presentation by DCs and activation of cytotoxic CD8 T cells, but also on the magnitude of CD4 Th reactivity (35, 36) . Indeed, vaccination of cancer patients with both Th epitopes and MHC class I binding motifs elicited enhanced HER2 peptide-specific CTL expansion and provided durable responses detectable more than 1 year after the final vaccination (37).
Nevertheless, HLA restriction limits the potential number of patients who can receive these vaccines, and the use of DNA plasmids coding for tumor antigens has therefore been shown to be advantageous (19) . Vaccines able to induce both CD8 and CD4 responses, and hence CTL and humoral immunity, are considered better than vaccines able to induce just one response. Vaccination with a xenogeneic antigen has been reported to be effective in overcoming the immunological tolerance to self-proteins (43) . Results obtained from transgenic mouse models demonstrated that vaccination with DNA plasmids coding for xenogeneic HER2 elicited a strong immunological response without cross-reaction (16) . Chimeric rat/human HER2 plasmids were most effective in blunting immune tolerance to both rat and human HER2, suggesting that the presence of heterologous regions enhances immunogenicity against the antigen (17, 18) . Thus, the self-sequence ensures the specificity of the immune response, while the xenogeneic part circumvents immune tolerance.
Increased levels of Treg cells were observed both in our cohort of patients, and in patients with different malignancies, and are often associated with worse outcomes (44) . Treg cells inhibit primary T-cell activation and are paradoxically expanded by tumor vaccines coding for self-sequences (45) (46) (47) (48) . Indeed, we show that HuHuT-DCs did not affect Treg 
